Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Intracerebral Hemorrhage
Phase Not Applicable
Enrollment 856
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigators design a prospective, observational cohort study to provide contemporary information on the prevalence, characteristics, risk stratification,cost-effective ,treatments and prognosis of Chinese hospitalised adult patients with intracerebral hemorrhage.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • proportion of patients with a 3-month modified Rankin Scale (mRS) score≤ 3 (2-3years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-12-29
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 856 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Principal Investigators:
  • Feng Gao, MD,PhD (PRINCIPAL_INVESTIGATOR) - Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
Feng Gao, MD,PhD
13588451471
2202012@zju.edu.cn
Lusha Tong, MD,PhD
15868171218
Feng Gao, MD,PhD
13588451471
2202012@zju.edu.cn
2nd Affiliated Hospital, School of Medicine at Zhejiang University
Interventions
N/A
Study Locations (1 sites)
2nd Affiliated Hospital, School of Medicine at Zhejiang University, Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: * Hospitalized patients over 18 years old of primary intracerebral hemorrhage. Exclusion Criteria: 1. patients of secondary intracerebral hemorrhage,such as hemorrhagic transformation of ischemic stroke, aneurysmal, cavernomas, arterio- venous malformations, central venous thrombosis, trauma-related, or tumor. 2. isolated intraventricular hemorrhage or subarachnoid hemorrhage pregnant patients; 3. surgical evacuation of hematoma; 4. unavailability to get complete blood cell samples and presenting contraindications or refusal to MRI 5. patients cannot be followed up for any reasons. 6. patients death in 24 hours 7. pregnant patients
Conditions Radiotracer, Hypertension, Cholesterol
Phase EARLY_PHASE1
Enrollment 6
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This exploratory, first-in-man, phase 0 study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\[18F\]FNP-59) to image the adrenal gland in healthy normal subjects. The researchers believe that \[18F\]FNP-59 would greatly improve the imaging characteristics, by providing a PET imaging cholesterol analogue with significantly improved radiation dosimetry.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Drug: FNP-59 — FNP-59, a radiotracer, is administered for PET/CT scans.

Primary Outcomes

  • Uptake for [18F]FNP-59 in the adrenal glands using the standardized uptake value (SUV) based on gland segmentation (Day 0)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2021-01-18
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 6 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Benjamin Viglianti
Principal Investigators:
  • Ben Viglianti, M.D, Ph.D. (PRINCIPAL_INVESTIGATOR) - University of Michigan
Contact Information
Study Contact:
Jim Pool
734-615-7391
jampool@umich.edu
James Pool
734-615-7391
jampool@umich.edu
University of Michigan
Benjamin Viglianti, M.D, Ph.D.
University of Michigan
Interventions
  • Drug: FNP-59 — FNP-59, a radiotracer, is administered for PET/CT scans.
Study Locations (1 sites)
University of Michigan, Ann Arbor, Michigan 48109 United States
Eligibility Criteria
Inclusion Criteria: * Participants without any known adrenal pathology as normal controls for radiation dosimetry purposes Exclusion Criteria: * Pregnancy * Unable to do imaging * Body weight greater than 400 lbs (181 Kg) * Prisoners are not eligible * Subjects unable to provide own consent are not eligible * Current use of steroids, Oral contraceptives (OCP), spironolactone, estrogen, androgen, progesterone, Angiotensin-converting enzyme (ACE inhibitors)/ Angiotensin II receptor blockers (ARBs), or supplements that are hormone analogues. * Known adrenal pathology
Conditions Dyslipidemia Associated With Type II Dia...
Phase PHASE3
Enrollment 228
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of Berlim 25/20 association in the treatment of type 2 diabetes mellitus and dyslipidemia.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: BERLIM 25/20 ASSOCIATION — Berlim 25/20 association coated tablet.
  • Other: EMPAGLIFLOZIN PLACEBO — Empagliflozin placebo coated tablet.
  • Other: ROSUVASTATIN CALCIUM PLACEBO — Rosuvastatin calcium placebo coated tablet.
  • Drug: EMPAGLIFLOZIN — Empagliflozin 25 mg coated tablet.
  • Drug: ROSUVASTATIN CALCIUM — Rosuvastatin 20 mg coated tablet.
  • Other: BERLIM 25/20 ASSOCIATION PLACEBO — Berlim 25/20 association placebo coated tablet.

Primary Outcomes

  • Reduction of glycated hemoglobin levels measured between the first visit and the last visit. (120 days)
  • Percentual reduction of LDL-c levels measured between the first visit and the last visit. (120 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-12-01
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 228 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: EMS
Contact Information
Study Contact:
Cassiano O Berto, BD
+551938877724
pesquisa.clinica@ncfarma.com.br
Mauro A Crippa, MD
Allergisa
Interventions
  • Drug: BERLIM 25/20 ASSOCIATION — Berlim 25/20 association coated tablet.
  • Other: EMPAGLIFLOZIN PLACEBO — Empagliflozin placebo coated tablet.
  • Other: ROSUVASTATIN CALCIUM PLACEBO — Rosuvastatin calcium placebo coated tablet.
  • Drug: EMPAGLIFLOZIN — Empagliflozin 25 mg coated tablet.
  • Drug: ROSUVASTATIN CALCIUM — Rosuvastatin 20 mg coated tablet.
Study Locations (1 sites)
Allergisa, Campinas, São Paulo Brazil
Eligibility Criteria
Inclusion Criteria: * Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; * Participants of both sexes, with age greater than or equal to 18 years and less than or equal to 85 years; * Participants presenting the diagnosis of type II diabetes mellitus, and who did not reach the therapeutic goals of HbA1c with previous dietary, physical exercise guidance and previous therapies at a stable dose in the last 3 months; * HbA1c ≥ 7,5% and ≤ 10,5% and fasting blood glucose \> 100 mg/dL at the screening visit; * Participants with high or very high cardiovascular risk according to the Brazilian guideline on the prevention of cardiovascular diseases in patients with diabetes (2017), which have not reached the goal of LDL-c ≤ 70 mg/dL or ≤ 50 mg/dL, respectively, with lifestyle changes, who are or aren't using low or moderate potency statins; * BMI (body mass index) \> 19 Kg/m2 and ≤ 45 Kg/m2. Exclusion Criteria: * Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants; * History of alcohol abuse or illicit drug use; * Participation in a clinical trial in the year prior to this study; * Pregnancy or risk of pregnancy and lactating patients; * Known hypersensitivity to the formula components used during the clinical trial; * Type 1 diabetes mellitus; * Fasting blood glucose \> 300 mg/dL; * Risk factors for volume depletion; * Participants with total cholesterol \> 500 mg/dL or triglycerides \> 500 mg/dL; * Impaired renal function and end-stage renal disease; * Participants with known heart failure, class III to IV (New York Heart Association); * Impaired hepatic function; * Medical history of pancreatic diseases that may suggest insulin deficiency; * Participants who had any cardiovascular event (acute myocardial infarction, acute coronary syndrome, recent onset stable angina, stroke, unstable congestive heart failure requiring treatment change), underwent revascularization or vascular surgery in the 6 months prior to screening; * Bariatric surgery in the last two years and/ or other gastrointestinal surgeries that can cause chronic malabsorption syndrome; * Condition that, in the investigator's judgment, may favor clinically significant changes in CPK levels; * Current medical history of cancer and/ or cancer treatment in the last 5 years; * Participants with known uncontrolled hypothyroidism or TSH levels \> 5 mIU/L; * History of known muscle disease or prior statin intolerance; * Participants using SGLT2 inhibitors, sulfonylureas and/or insulin therapy or PCSK9 inhibitors; * Participants who used other medications with prominent action in the control of serum triglyceride and cholesterol levels in the last 4 weeks or who are using low or moderate-intensity statins that cannot be replaced by rosuvastatin 20 mg; * Participants using medications that may interfere with triglyceride and cholesterol metabolism started less than 4 weeks ago or with dose adjustment in the last 4 weeks prior to the screening visit; * Treatment with anti-obesity drugs for less than 2 months or with dose change in the last 2 months.
Conditions Diabetes Mellitus, Type 2, Heart Failure...
Phase Not Applicable
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Type 2 diabetes is a risk factor of heart failure and cognitive decline. Heart failure at its early stage is often silent. At present, primary prevention for heart failure is not available. Our aim is to identify diabetic patients at risk of heart failure in order to develop personalized preventive strategies. Type 2 diabetes is vascular and metabolic risk factor for cognitive decline though a direct lesional effect but also through an interaction with underlying neurodegenerative lesions. Our aim is to identify diabetic patients at risk of cognitive decline in order to develop personalized preventive strategies

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Heart failure (≥ stade B). (at 48 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-06-22
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Lille
Principal Investigators:
  • Charlotte Cordonnier, MD,PhD (PRINCIPAL_INVESTIGATOR) - University Hospital, Lille
Contact Information
Study Contact:
Charlotte Cordonnier, MD,PhD
0320445962
precidiab_heart_brain@chru-lille.fr
0320445962
Hopital Roger Salengro, CHU Lille
Charlotte Cordonnier, MD,PhD
Hopital Roger Salengro, CHU Lille
Interventions
N/A
Study Locations (1 sites)
Hopital Roger Salengro, CHU Lille, Lille, 59037 France
Eligibility Criteria
Inclusion Criteria: * Adults * Persons able to understand and object to the information provided. * Type 2 diabetic patient free of heart failure ≥stade B * Patient affiliated with a social security scheme. * Patient agreeing to sign the informed consent form Exclusion Criteria: * Patient with dementia * Patient with at least one of the criteria for heart failure ≥stade B
Conditions Breast Cancer Female, Estrogen Receptor ...
Phase PHASE3
Enrollment 3360
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Given the compelling evidence supporting a protective effect of statins on breast cancer recurrence, calls for prospective clinical trials have been expressed. In this trial - the MASTER trial - we hypothesize that the addition of statin treatment to the current breast cancer treatment will improve the prognosis of women with early breast cancer. This trial is designed as follows: a randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Atorvastatin 80 Mg Oral Tablet — Atorvastatin 80 mg per day for 2 years
  • Drug: Placebo oral tablet — Placebo 1 tablet per day for 2 years

Primary Outcomes

  • Invasive disease-free survival (10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2021-01-04
Completion: 2035-01-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 3360 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aarhus University Hospital
Collaborators: Rigshospitalet, Denmark, Hospital of Southern Jutland, University of Copenhagen, Bornholms Hospital, Naestved Hospital, Vejle Hospital, Odense University Hospital, Nordsjaellands Hospital, Aalborg University Hospital, Herning Hospital
Principal Investigators:
  • Signe SB Borgquist, MD, PhD (PRINCIPAL_INVESTIGATOR) - Aarhus University Hospital
Contact Information
Study Contact:
Signe SB Borgquist, MD, PhD
004522624525
signe.borgquist@auh.rm.dk
Signe SB Borgquist, MD, PhD
004522624525
signe.borgquist@auh.rm.dk
Aarhus University Hospitak
Interventions
  • Drug: Atorvastatin 80 Mg Oral Tablet — Atorvastatin 80 mg per day for 2 years
  • Drug: Placebo oral tablet — Placebo 1 tablet per day for 2 years
Study Locations (1 sites)
Aarhus University Hospitak, Aarhus, Denmark
Eligibility Criteria
Patients must meet ALL of the following criteria to be eligible for randomization: Inclusion Criteria: 1. Women with estrogen receptor positive breast cancer who are candidates for (neo)adjuvant systemic therapy OR have received ≤3 years of adjuvant endocrine therapy. 2. Age \> 18 years. 3. Performance status of ECOG ≤ 2. 4. Prior to patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations. Patients meeting ANY one of the following criteria are not eligible: Exclusion Criteria: 1. History of any prior (ipsi- and/or contralateral) invasive breast carcinoma. 2. Ongoing (prevalent) cholesterol-lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors). If so, the patient can be enrolled in the observational arm. 3. Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range) or renal dysfunction (creatinine level more than three times the upper limit of the normal range). 4. Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle - or liver disease, or excessive alcohol consumption AND creatine kinase (CK) measured to less than five times the upper limit (CK only measured in case of predisposing factors). 5. No current medication with potent CYP3A4-inhibitors (e.g. ketokonazole, erythromycin) or gemfibrozile, cyclosporin or danazol. 6. Pregnancy or breast-feeding. 7. Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial. 8. History of allergic reactions attributed to compounds of similar chemical or biological composition to atorvastatin.
Conditions Advanced Solid Tumor, Advanced Malignant...
Phase PHASE1, PHASE2
Enrollment 300
Locations 77 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: rezatapopt — First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
  • Drug: pembrolizumab — Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.

Primary Outcomes

  • Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt (40 months)
  • Phase 1 Monotherapy (Dose Escalation): Establish the Recommended Phase 2 Dose (RP2D) (30 months)
  • Phase 1 Monotherapy (Dose Escalation): Establish the maximum tolerated dose (MTD) (Phase 1) (The first 28 days of treatment (Cycle 1) per patient)
  • Phase 1b Combination Therapy (Part 1: Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt when administered in combination with pembrolizumab (18 months for treatment arm)
  • Phase 1b Combination Therapy (Part 1: Dose Escalation): Establish the maximum tolerated dose (MTD) of rezatapopt when administered in combination with pembrolizumab (The first 28 days of combination treatment arm (starting on Day -7) per patient)
  • Phase 1b Combination Therapy (Part 1: Dose Escalation): Establish the Recommended Phase 2 Dose (RP2D) of rezatapopt when administered in combination with pembrolizumab (18 months)
  • Phase 1b Combination Therapy (Part 2: Dose Expansion): Determine the number and type of adverse events to characterize the safety of rezatapopt when administered in combination with pembrolizumab (12 months for treatment arm)
  • Phase 2 Monotherapy (Dose Expansion): Response rate assessment to evaluate the clinical activity / efficacy of rezatapopt (34 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2020-10-29
Completion: 2027-12-31
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: PMV Pharmaceuticals, Inc
Collaborators: Merck Sharp & Dohme LLC
Principal Investigators:
  • Marc Fellous, MD (STUDY_DIRECTOR) - Sr. Vice President of Medical Affairs
Contact Information
Study Contact:
PMV Pharma Clinical Study Information Center
(609) 235-4038
clinicaltrials@pmvpharma.com
Shumei Kato, MD
University of San Diego Moores Cancer Center
Gottfried Konecny, MD
UCLA Jonsson Comprehensive Cancer Center
Interventions
  • Drug: rezatapopt — First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
  • Drug: pembrolizumab — Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
Study Locations (77 sites)
University of California Irvine Chao Family Comprehensive Cancer Center, Irvine, California 92868 United States
University of San Diego Moores Cancer Center, La Jolla, California 92093 United States
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California 90024 United States
USC Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
Rocky Mountain Cancer Center, Denver, Colorado 80218 United States
Yale Cancer Center, New Haven, Connecticut 06519 United States
Medical Oncology Hematology Consultants, Newark, Delaware 19713 United States
University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida 33136 United States
Advent Health, Orlando, Florida 32803 United States
Florida Cancer Specialists South, Port Charlotte, Florida 33980 United States
Eligibility Criteria
Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy with a TP53 Y220C mutation * Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 * Previously treated with one or more lines of anticancer therapy and progressive disease * Adequate organ function * Measurable disease per RECIST v1.1 (Phase 2) Additional Criteria for Inclusion in Phase 1b (rezatapopt) + pembrolizumab combination) * Anti-PD-1/PD-L1 naive or must have progressed on treatment * Measurable disease Exclusion Criteria: * Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug * Radiotherapy within 14 days of receiving the study drug * Primary CNS tumor * History of leptomeningeal disease or spinal cord compression * Brain metastases, unless neurologically stable and do not require steroids to treat associated neurological symptoms * Stroke or transient ischemic attack within 6 months prior to screening * Heart conditions such as unstable angina within 6 months prior to screening, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities * Strong CYP3A4 inducers and strong CYP2C9 inhibitors/inducers within 14 days of first dose of rezatapopt * History of gastrointestinal (GI) disease that may interfere with absorption of study drug or patients unable to take oral medication * History of prior organ transplant * Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer * Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection Additional Criteria for Exclusion from Phase 2 (rezatapopt monotherapy) * Known KRAS mutation, defined as a single nucleotide variant (SNV) (Phase 2) Additional Criteria for Exclusion from Phase 1b (rezatapopt) + pembrolizumab combination) * Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE) * Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention * Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy within 7 days prior to the first dose of study drug * Hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients * Active autoimmune disease that has required systemic treatment in past 2 years * History of radiation pneumonitis * History of (non-infectious) or active pneumonitis / interstitial lung disease that required steroids * Active infection requiring systemic therapy * Known history of HIV infection * Has previously received rezatapopt
Conditions Breast Cancer, Digestive Cancer, Gynecol...
Phase NA
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Circulating tumor DNA (ctDNA) offers the possibility of accessing the tumor genome from circulating blood through a simple blood test. It is currently used for diagnostic, prognostic and predictive purposes of response or resistance to oncological treatments. These advances in ctDNA have been made possible by major developments in molecular biology techniques in recent years, as the detection of ctDNA requires very sensitive techniques such as Next Generation Sequencing (NGS). CtDNA overcomes this problem of very limiting tumor heterogeneity during a solid biopsy. All of these applications make circulating DNA an increasingly essential tool in the management of cancer patients. The studies are currently in most cases on small numbers and are retrospective. In addition, exosomes are also a biomarker of the future that can also be detected in the bloodstream . Exosomes are nanovesicles 50 to 200 nm in diameter released into the extracellular environment via the endosomal pathway by fusion with the plasma membrane. They are very informative since they transport tumor genetic material in the form of DNA, mRNA and miRNA, but also adhesion proteins, immunostimulatory molecules and cytoskeleton, enzymes and Heats shock proteins ( HSP). The aim of the ADIGYN study is to set up a large prospective cohort to assess the diagnostic, prognostic and predictive impact of ctDNA and exosomes in digestive and gynecological / breast cancers. From the circulating DNA, we characterize the ActDNA on the molecular level thanks to the study of different point mutations usually used but also of new described mutations having a therapeutic impact and the search for other genetic alterations having an impact on the therapeutic strategy (such as microsatellite instability) or the study of exosomes and their composition. To assess resistance to oncological treatments, ctDNA will be analyzed at the start of treatment, during treatment, during progression and / or relapse and also during monitoring or treatment break

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Blood samples — Only blood samples at different times of treatment

Primary Outcomes

  • To assess the prognostic impact of ctDNA (mortality) in digestive and gynecological / breast cancers. (Through study completion, an average of 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-03-08
Completion: 2032-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Poitiers University Hospital
Contact Information
Study Contact:
Camille EVRARD, PHD
+33549444279
camille.evrard@chu-poitiers.fr
Camille EVRARD, Dr
CHU POitiers
Interventions
  • Diagnostic Test: Blood samples — Only blood samples at different times of treatment
Study Locations (1 sites)
CHU POitiers, Poitiers, France
Eligibility Criteria
Inclusion Criteria: * Digestive or gynecological / breast cancer proven or suspected, requiring oncological treatment (chemotherapy or immunotherapy) * Major patient * Patients benefiting from a Social Security scheme or benefiting through the intermediary of a third party * Information note and collection of non-opposition after clear and fair information about the study Exclusion Criteria: * Linguistic or psychological refusal or inability to understand and / or sign the information and no-objection note * History of a cancer other than that allowing inclusion in the 5 years preceding inclusion
Conditions Psychotic Disorders, ADHD, TBI (Traumati...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Forensic patients often display cognitive deficits, particularly in the domain of executive functions, that represent a challenge to forensic rehabilitation. One empirically-validated method to train executive functions is cognitive remediation, which consists of cognitive exercises combined with coaching. This trial investigates whether cognitive remediation can improve cognitive, functional, and clinical outcomes in forensic inpatients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Cognitive Remediation — Cognitive Remediation consists of exercises, preferably supported by coaching, aimed at engaging cognitive skills and, as a result, at improving cognition as well as functional and clinical outcomes.
  • Behavioral: Active Control — Active control condition for cognitive remediation, matched in terms of session modality, number, duration, frequency, and format.

Primary Outcomes

  • Executive Function (within 1 week prior and 1 week after training, as well as at a 12-week follow-up.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-02-10
Completion: 2026-02-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Royal Ottawa Mental Health Centre
Principal Investigators:
  • Patrizia Pezzoli, PhD (PRINCIPAL_INVESTIGATOR) - UCL and The Royal's Institute of Mental Health Research
Contact Information
Study Contact:
Patrizia Pezzoli, PhD
613-722-6521
p.pezzoli@ucl.ac.uk
Tammy Beaudoin
(613) 722-6521
Tammy.Beaudoin@theroyal.ca
The Royal's Institute of Mental Health Research
Patrizia Pezzoli, PhD
The Royal's Institute of Mental Health Research
Interventions
  • Behavioral: Cognitive Remediation — Cognitive Remediation consists of exercises, preferably supported by coaching, aimed at engaging cognitive skills and, as a result, at improving cognition as well as functional and clinical outcomes.
  • Behavioral: Active Control — Active control condition for cognitive remediation, matched in terms of session modality, number, duration, frequency, and format.
Study Locations (1 sites)
The Royal's Institute of Mental Health Research, Ottawa, Ontario K1Z 7K4 Canada
Eligibility Criteria
Inclusion Criteria: i1. Age 18 - 55; i2. Ability to read and speak in fluent English; i3. Current status as inpatient on the Forensic Treatment Unit. Exclusion Criteria: e1. Intellectual disability; e2. TBI with loss of consciousness followed by known severe neurological sequelae requiring hospitalisation and rehabilitation.
Conditions Eosinophilic Asthma, EGPA - Eosinophilic...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Introduction: The etiology and therapy of eosinophilic lung diseases are still poorly understood. For individual forms of disease, such as eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA), new therapeutic approaches exist that block the interleukin IL-5 or the IL-5 receptor. Eosinophilic manifestations of the respiratory tract can exclusively affect the lungs or occur as part of a systemic disease. The manifestations partially overlap and are clinically difficult to differentiate (e.g. eosinophilic asthma, Samter Triad, EGPA or hypereosinophilic syndrome (HES)). It is now known that blood eosinophil counts correlate with the level of eosinophils recruited to the airways. However, it is still unclear whether there is a blood eosinophilia without clinical relevance or whether there is a risk of organ damage (e.g. in HES). Hence, different subtypes of eosinophils with different polarization are discussed. Aim of the study: A registry of patients with eosinophilia and respiratory manifestation will be established at the University Hospital of Innsbruck. The course of disease will be evaluated prospectively in a non-interventional study. This study stands on three main clinical pillars with focus on further characterization of eosinophilic cells: 1. Patients will be included who switch from a previous application of the anti-IL5 antibody mepolizumab (production and administration of the injection from lyophysate through the doctor) to the pre-mixed pen (self-injection at home). 2. Furthermore, special focus is set on patients suffering from the so-called Samter Triad. In these patients, the control of asthma, nasal polyps and NSAID intolerance will be examined in an interdisciplinary fashion during the course of treatment. 3. Previous clinical studies at our Department indicate that some patients with severe eosinophilic asthma or Samter Triad could represent a mono-organic or limited manifestation of lymphoid HES. This hypothesis is tested by measuring additional chemokines, somatic mutations and FACS parameters in this subgroup to verify a clonal disease. In addition, translational research will differentiate resident and inflammatory eosinophilic granulocytes by FACS analysis and further characterize them by fluorescence microscopy, electron microscopy, gene chip analysis and lipidomics, in the above-mentioned diseases and in healthy controls, respectively. Patients and methods: All patients suffering from eosinophilia with pulmonary involvement who are diagnosed with eosinophilic asthma, EGPA, Samter Triad, HES, and eosinophilic pneumonia with signed consent are included in the prospective registry. Provided, that they are registered at the outpatient department of pneumology, ENT, haematology or allergology at the University Hospital Innsbruck. The investigators will collect laboratory analyses, lung function, imaging, bone marrow biopsies, ENT findings and allergological findings over the course of the study…

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Other: no intervention — no intervention

Primary Outcomes

  • Establishment of a registry and descriptive characterization of the collective (frequencies of the individual types of disease, frequencies of the forms of therapy, documentation of the clinical course). (10 years)
  • Identification of inflammatory and regulatory eosinophils in peripheral blood by FACS analysis in all subtypes of eosinophilic manifestations of the respiratory tract (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-02-26
Completion: 2030-02-26
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University Innsbruck
Contact Information
Study Contact:
Ivan Tancevski, MD
+43 50504 81602
ivan.tancevski@i-med.ac.at
Judith Löffler-Ragg
+43 50504 81413
judith.loeffler@i-med.ac.at
Ivan Tancevski, MD
+43 50504 81602
ivan.tancevski@i-med.ac.at
University Clinic for Internal Medicine II
Interventions
  • Other: no intervention — no intervention
Study Locations (1 sites)
University Clinic for Internal Medicine II, Innsbruck, 6020 Austria
Eligibility Criteria
Inclusion Criteria: * age ≥ 18 years * documented blood eosinophilia ≥ 300 cells/µl * present tissue damage of the respiratory tract caused by eosinophils Exclusion Criteria: * age \< 18 years * pregnancy * dementia * incapacitated patients
Conditions Major Depressive Disorder
Phase NA
Enrollment 124
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will explore the mechanisms of change that are activated when individuals receive a treatment that targets their weakness and the mechanisms activated when the treatment capitalize on their strength. Patients will be assigned to one of two types of psychotherapies in treating people with a major depression disorder, expressive-supportive vs. emotion-focused treatment. Their ability to benefit from treatment based on their pre-treatment levels of insight and emotional processing will be examined. This is a four-month protocol, with a 2 year follow up period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Supportive-expressive treatment — Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
  • Behavioral: Emotions-Focused treatment — Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.

Primary Outcomes

  • Weekly change in Hamilton rating scale for depression (HRSD) (up to 16 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-11-29
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Haifa
Collaborators: Israel Science Foundation
Contact Information
Study Contact:
Sigal Zilcha-Mano, PhD
972-8249047
sigalzil@gmail.com
Sigal Zilcha-Mano, PhD
972-8249047
sigalzil@gmail.com
University of Haifa
Tohar Dolev-Amit, M.A.
972-8249047
tohardolev@gmail.com
University of Haifa
Interventions
  • Behavioral: Supportive-expressive treatment — Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
  • Behavioral: Emotions-Focused treatment — Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.
Study Locations (1 sites)
University of Haifa, Haifa, Israel
Eligibility Criteria
Inclusion Criteria: * Meeting major depressive disorder diagnostic criteria using the structured clinical interviews for Diagnostic and Statistical Manual of Mental Disorders-5 and scoring more than 14 on the 17-item Hamilton rating scale for depression at two evaluations (one week apart) (Hamilton, 1967). * If on medication, patients' dosage must be stable for at least three months prior to entering the study, and they must be willing to maintain stable dosage for the duration of treatment * Age between 18 and 65 * Hebrew language fluency * Provision of written informed consent. Exclusion Criteria: * Current risk of suicide or self-harm * current substance abuse disorders * current or past schizophrenia or psychosis, bipolar disorder, or severe eating disorder requiring medical monitoring * history of organic mental disease * currently in psychotherapy
Conditions Skin Toxicity
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to study a Chinese herbal Complementary and Alternative Medicine (CAM) product for the temporary relief of pain and itching after radiotherapy (RT). This is an over-the-counter product with 1% menthol as an active ingredient.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Complementary and alternative medicine (CAM) — CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.

Primary Outcomes

  • Proportion of patients free of clinically relevant skin toxicities (Up to 18 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-07-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Miami
Collaborators: VAUGHN-JORDAN FOUNDATION, INC., Florida Breast Cancer Foundation
Principal Investigators:
  • Jennifer J Hu, PhD (PRINCIPAL_INVESTIGATOR) - U. of Miami
Contact Information
Study Contact:
Jennifer J Hu, PhD
3052437796
jhu@med.miami.edu
Jennifer J Hu, PhD
305-243-7796
jhu@med.miami.edu
University of Miami
Jennifer J Hu, PhD
University of Miami
Interventions
  • Other: Complementary and alternative medicine (CAM) — CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.
Study Locations (1 sites)
University of Miami, Miami, Florida 33136 United States
Eligibility Criteria
Inclusion Criteria: * Female subjects with newly diagnosed breast carcinoma * \> 18 years of age * Post-mastectomy with or without reconstruction * Stage II-IIIb with any receptor status * All races and ethnicities are eligible * Patients must be able to consent in English or Spanish * Plan to receive adjuvant radiotherapy to the chest wall +/- regional lymph nodes * RT will involve standard fractionation use of 3D conformal or Intensity-modulated RT (IMRT) * Willing to sign protocol consent form * Patients are allowed to receive adjuvant hormonal therapy and/or targeted therapies such as trastuzumab prior to, during and/or after radiation therapy. * Patients may receive chemotherapy before or after radiation therapy Exclusion Criteria: * Prior radiation to the involved breast or chest wall * Concurrent chemotherapy * Unable or unwilling to sign informed consent * Unable to speak English or Spanish * Pregnant women * Clinical or pathologic stage T4 * Metastatic disease * Connective tissue disorder including Systemic Lupus Erythematosus and Scleroderma
Conditions Locally Advanced or Metastatic ER+ HER2-...
Phase PHASE2
Enrollment 320
Locations 44 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: PF-07248144 — KAT6 Inhibitor
  • Drug: Fulvestrant — Endocrine Therapy
  • Drug: Letrozole — Endocrine Therapy
  • Drug: Palbociclib — CDK4/6 Inhibitor
  • Drug: PF-07220060 — CDK4 inhibitor
  • Drug: PF-07850327, ARV-471, vepdegestrant — PROTAC (PROteolysis Targeting Chimera) ER degrader

Primary Outcomes

  • Number of participants with dose-limiting toxicities in the Dose Escalation Arms. (Up to 29 days)
  • Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Escalation Arms. (Up to 24 months)
  • Safety and Tolerability through monitoring of laboratory assessments for participants enrolled in the Dose Escalation Arms. (Up to 24 months)
  • Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Expansion Arms (Up to 24 months)
  • Safety and Tolerability through monitoring of laboratory assessments for participants enroled in the Dose Expansion Arms (Up to 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2020-11-16
Completion: 2029-08-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pfizer
Principal Investigators:
  • Pfizer CT.gov Call Center (STUDY_DIRECTOR) - Pfizer
Contact Information
Study Contact:
Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com
Interventions
  • Drug: PF-07248144 — KAT6 Inhibitor
  • Drug: Fulvestrant — Endocrine Therapy
  • Drug: Letrozole — Endocrine Therapy
  • Drug: Palbociclib — CDK4/6 Inhibitor
  • Drug: PF-07220060 — CDK4 inhibitor
Study Locations (44 sites)
HonorHealth, Scottsdale, Arizona 85258 United States
Cedars Sinai Medical Center, Los Angeles, California 90048 United States
Cedars-Sinai Cancer at Cedars-Sinai Medical Center, Los Angeles, California 90048 United States
UCSF Medical Center at Mission Bay, San Francisco, California 94158 United States
Smilow Cancer Hospital at Yale - New Haven, New Haven, Connecticut 06510 United States
Yale-New Haven Hospital- Yale Cancer Center, New Haven, Connecticut 06510 United States
Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut 06511 United States
Yale University, New Haven, Connecticut 06511 United States
Holy Cross Hospital, Fort Lauderdale, Florida 33308 United States
St. Elizabeth Healthcare, Edgewood, Kentucky 41017 United States
Eligibility Criteria
Inclusion Criteria: * Disease Characteristics - Breast, Prostate, and Lung Cancer * Part 1A (Monotherapy Dose Escalation) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer, CRPC, or NSCLC that is intolerant or resistant to standard therapy or for which no standard therapy is available. * Part 1B, Part 1C, Part 1D and Part 1E (Combination Dose Escalation) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants must have progressed after at least 1 prior line of treatment with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting. * Part 2A (ER+HER2- breast cancer 2L+, monotherapy) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants must have progressed after at least 1 prior line of CDK4/6 inhibitor and 1 line of endocrine therapy. * Part 2B (ER+HER2- breast cancer 2-4L, combination with fulvestrant) Histological or cytological diagnosis of advanced or metastatic ER+HER2- breast cancer. Participants must have progressive disease after at least 1 prior line of a CDK4/6 inhibitor and at least 1 prior line of endocrine therapy.. Participants must not have received more than 3 prior lines of systemic therapies including up to 1 line of cytotoxic chemotherapy for visceral disease in advanced or metastatic setting; Participants may have but are not required to have prior treatment with fulvestrant. * Part 2D (ER+HER2- breast cancer 2-4L, combination with PF-07220060 (CDK4i) and fulvestrant): Histological or cytological diagnosis of advanced or metastatic ER+HER2- breast cancer. Participants must have progressive disease after at least 1 prior line of a CDK4/6 inhibitor and at least 1 prior line of endocrine therapy. * Participants must have not received more than 3 lines of systemic therapies including up to 1 line of cytotoxic chemotherapy for visceral disease in advanced or metastatic setting; Participants may have but are not required to have prior treatment with fulvestrant. * Part 2E (ER+HER2- breast cancer 2-4L, combination with vepdegestrant): Histological or cytological diagnosis of advanced or metastatic ER+HER2- breast cancer. Participants must have progressive disease after at least 1 prior line of a CDK4/6 inhibitor and at least 1 prior line of endocrine therapy; Participants must have not received more than 3 lines of systemic therapies including up to 1 line of cytotoxic chemotherapy for visceral disease in advanced or metastatic setting; Participants may have received fulvestrant * Participants with ER+HER2- advanced or metastatic breast cancer must have documentation of ER-positive tumor (≥1% positive stained cells) based on most recent tumor biopsy utilizing an assay consistent with local standards. * Participants with ER+HER2- advanced or metastatic breast cancer must have documentation of HER2-negative tumor: HER2-negative tumor is determined as immunohistochemistry score 0/1+ or negative by in situ hybridization (FISH/CISH/SISH/DISH) defined as a HER2/CEP17 ratio \<2 or for single probe assessment a HER2 copy number \<4. * Female participants with ER+HER2- advanced or metastatic breast cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause by treatment with the approved LHRH agonist such as goserelin, leuprolide or equivalent agents to induce chemical menopause. * Female participants with ER+HER2- advanced or metastatic breast cancer of nonchildbearing potential must meet at least 1 criteria of achieving postmenopausal status. * Participants must have at least 1 measurable lesion as defined by RECIST version 1.1 that has not been previously irradiated. * Eastern Cooperative Oncology Group (ECOG) Performance Status PS 0 or 1 * Female or male patients aged ≥ 18 years (Japan ≥ 20 years) (South Korea ≥ 19 years). * Adequate renal, liver, and bone marrow function. * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for adverse events (AEs) not constituting a safety risk by investigator judgment. Exclusion Criteria: * Unmanageable ascites (limited medical treatment to control ascites is permitted, but all participants with ascites require review by sponsor's medical monitor). * Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ. * Major surgery, radiation therapy, or systemic anti-cancer therapy within 3 weeks prior to study entry. * Prior irradiation to \>25% of the bone marrow. * ECG clinically relevant abnormalities (eg, QTc \>470 msec, complete LBBB, second/third degree AV block, ST elevation or EKG changes suggesting myocardial infarction or active myocardia ischemia). * Therapeutic anticoagulation. However, low molecular weight heparin is allowed. Vitamin K antagonists or factor Xa inhibitors may be allowed following discussion with the Sponsor. * Known or suspected hypersensitivity or severe allergy to active ingredient/excipients of PF-07248144. * Active inflammatory GI disease, refractory and unresolved chronic diarrhea or previous gastric resection, lap band surgery or other GI conditions and surgeries that may significantly alter the absorption of PF-07248144 tablets. Gastroesophageal reflux disease under treatment is allowed. * Pregnant or breastfeeding female participants.